Havilland Campbell

Statistics

Publications

Citations

426

H-Index

Active since

2009

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

University of North Carolina at Chapel Hill

Havilland Campbell is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in antiviral pharmacotherapy, antiretroviral therapy, and pharmacy.

Publications per year

2009–2023

Publications

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial

Joseph J. Eron, Jürgen K. Rockstroh, Jacques Reynes et al. · The Lancet Infectious Diseases · 2011 · 191 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +8

Sustained Antiretroviral Effect of Raltegravir After 96 Weeks of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection

Martin Markowitz, Bach‐Yen Nguyen, Eduardo Gotuzzo et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2009 · 110 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected Patients

Matthew L. Rizk, Yaming Hang, Wen‐Lin Luo et al. · Antimicrobial Agents and Chemotherapy · 2012 · 93 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +16

Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

Chloe Orkin, Jean‐Michel Molina, Pedro Cahn et al. · The Lancet HIV · 2023 · 32 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15

1–4 of 4